Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and applicable to a range of challenging, validated targets with high potential.
In the company’s own words · 10-K filed Mar 19, 2026 · SEC EDGAR
For the full year FY2025, revenue was $1.3M (+550% year on year) and net income −$140M.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.